Page 155 - Haematologica Vol. 110 - January 2025

ARTICLE - R-GemOx+Atezo in R/R transformed DLBCL
toxicities were manageable. With the caveat of the small sample size, response rates were numerically higher in the FL cohort than in the non-FL cohort, although pro- gression-free survival and overall survival were similar in the two groups. Durable responses were observed and appeared to be longer for those who achieved a complete response than in those who had a partial response. Nota- bly, over a quarter of patients enrolled were successfully transitioned to autologous HSCT or CAR T-cell therapy. However, there was a rare but fatal complication with this regimen, Stevens-Johnson syndrome, which is known to occur with PD-1/PD-L1 blockade.28 Although uncommon,
A
T. Othman et al. severe immune toxicities are an important limitation of
using regimens that incorporate PD-1 blockade into ther- apy for DLBCL.
Although R-GemOx previously demonstrated overall and complete response rates of 61% and 44%, respectively, in DLBCL,29 the patient population in that study is not directly comparable to ours: in the previous study the cohort pre- dominately consisted of de novo DLBCL patients receiving second-line therapy, and none had RT. Moreover, the man- agement of R/R DLBCL has evolved significantly since the original R-GemOx studies were conducted. Our trial was carried out more recently, with some patients having re-
B
Haematologica | 110 January 2025
147
Continued on following page.